accountLtd. (530019. BY) said Tuesday its unit Jubilant Biosys has extended its drug-discovery collaboration with U.S.-based Eli Lilly & Co. (LLY) by five years. In a statement to the Bombay Stock Exchange, Jubilant said Eli Lilly will fund the unit's research...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Jubilant Unit, Eli Lilly Extend Drug-Discovery Pact By 5 Years
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account